Special Issue "HIV Drug Resistance"

Guest Editor
Dr. Vinay Pathak
HIV Drug Resistance Program, National Cancer Institute NCI-Frederick, P.O. Box B, Building 535, Frederick, MD 21702-1201, USA
Website: http://home.ncifcrf.gov/hivdrp/Pathak.html
E-Mail:
Interests: viral and host factors that generate mutations in HIV-1 and MLV; antiviral drug resistance, in vivo reverse transcription

Submission Information

All papers should be submitted to viruses@mdpi.org. To be published continuously until the deadline and papers will be listed together at the special issue website.

Submitted papers should not have been published nor be under consideration for publication elsewhere. All papers are refereed through a peer-review process. A guide for authors is available on the Instructions for Authors page. Viruses is a new international, peer-reviewed, quarterly open access journal published by Molecular Diversity Preservation International.

Article Processing Charges (APC) for publication in this Open Access journal are waived for well-prepared manuscripts submitted by 30 June 2010. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

to be added soon

Type of Paper: Review
Title: Gag and Resistance
Author: Francois Clavel
E-Mail: francois.clavel@inserm.fr

Type of Paper: Review
Title: HIV Genotype/Phenotype Relationships in Drug Resistance
Author: Robert Shafer
E-Mail: rshafer@stanford.edu

Type of Paper: Review
Title: Resistance to RT Inhibitors and Mutations in Connection/RNase H Domains of Reverse Transcriptase
Author: Vinay K. Pathak
E-Mail: vpathak@ncifcrf.gov

Type of Paper: Review
Title: HIV Drug Resistance in Non-B Subtypes
Author: Marcelo Soares
E-Mail: masoares@inca.gov.br

Type of Paper: Review
Title: Resistance to Integrase Inhibitors
Author: Yves Pommier
E-Mail: pommier@nih.gov

Type of Paper: Review
Title: HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that are competing with the nucleotide substrate
Authors: Eric Ennifar¹, Giovanni Maga² and Maurizio Botta³
Affiliation: ¹Architecture et Réactivité des ARN, Université de Strasbourg, CNRS, 15 rue René Descartes, F-67084 Strasbourg, France
²Istituto di Genetica Molecolare, IGM-CNR, Via Abiategrasso 207, 27100 Pavia, Italy
³Dipartimento Farmaco Chimico Tecnologico, University of Siena, Via Alcide de Gasperi 2, 53100 Siena, Italy
E-Mails: e.ennifar@ibmc.u-strasbg.fr (E.E.), maga@igm.cnr.it (G.M.), botta@unisi.it (M.B.)
Abstract: HIV-1 reverse transcriptase (RT) inhibitors currently used in antiretroviral therapy are divided into two classes: (i) nucleoside analogue RT inhibitors (NRTIs), that compete with natural nucleoside substrate and act as terminator of proviral DNA synthesis, and (ii) non-nucleoside RT inhibitors (NNRTIs), that bind to a hydrophobic pocket close to the RT active site. In spite of the efficiency of NRTIs and NNRTIs used in combination therapy, the rapid emergence and spread of multidrug-resistant mutations requires the development of new RT inhibitors with an alternative mechanism of action. Recently, several studies reported the discovery of novel non-nucleoside inhibitors with a distinct mechanism of action. Unlike classical NNRTIs, they compete with the nucleotide substrate, thus forming a new class of RT inhibitors: nucleotide-competing RT inhibitors (NcRTIs). In this review, we discuss current progress in the understanding of the peculiar behaviour of these compounds.

Type of Paper: Review
Title: Molecular Basis for Drug Resistance in HIV-1 Protease
Author: Celia Schiffer and colleagues
E-Mail: Celia.Schiffer@umassmed.edu

Type of Paper: Review
Title: Clinical Management of HIV Drug Resistance
Author: Frank Maldarelli
E-Mail: fmalli@mail.nih.gov

Type of Paper: Review
Title: Resistance to Entry Inhibitors
Author: Eric Arts
E-Mail: eja3@case.edu